金十图示：2025年06月27日（周五）美股热门股票行情一览（美股收盘） 7348.17亿市值 977.39亿市值 7755.37亿市值 775.34 287.05 97.18 -1.70(-0.59%) +1.16(+1.21%) -19.78(-2.49%) 甲骨文 奈飞 VISA 维萨 6433.34亿市值 5906.68亿市值 5631.37亿市值 210.29 348.66 1323.25 +2.63(+0.76%) -2.53(-1.19%) +16.58(+1.27%) PaG 宝浩 3747.05亿市值 埃克森美孚 万事达 4999.17亿市值 4713.02亿市值 159.82 550.54 109.36 -0.63(-0.57%) +4.73(+0.87%) +1.19(+0.75%) 美国银行 国 家得宝 == 强生 1711 3668.20亿市值 3548.27亿市值 3666.62亿市值 368.69 152.39 47.11 +5.19(+1.43%) +0.38(+0.25%) -0.35(-0.74%) t | 联合健康 ASML 阿斯麦 @gg 可口可乐 3130.58亿市值 ...

2206.36亿中值 2240.91亿中值 2191.45亿中值 121.90 139.68 314.93 -0.07(-0.05%) +3.51(+1.13%) +0.44(+0.36%) m 麦当劳 2052.75亿市值 oldma, 高感 = 美国电话电报 AT&T 2014.77亿市值 2115.09亿市值 689.31 287.08 28.00 +2.15(+0.31%) 0.00(0.00%) +1.46(+0.51%) 加拿大皇家银行 CAT 卡特彼勒 (圖片) Uber 优步 1908.30亿市值 1841.09亿市值 1803.80亿市值 91.25 130.52 383.53 -1.86(-2.00%) +0.35(+0.27%) +1.65(+0.43%) 威瑞森通讯 量量 Q 高通 1777.08亿市值 1771.57亿市值 1755.43亿市值 42.15 129.21 159.88 +0.05(+0.11%) +0.99(+0.77%) +1.69(+1.07%) 贝莱德 奥多比 SONY 紫尼 BLACKROCK 貝蕉禮 1637.48亿市值 1611.23亿市值 1582.42 ...

金十图示：2025年06月26日（周四）美股热门股票行情一览（美股盘中） 7691.13亿市值 7542.93亿市值 8027.28亿市值 96.38 795.89 288.85 -0.89(-0.91%) +4.79(+1.68%) +3.59(+0.45%) 甲骨文 奈飞 VISA 维萨 6359.99亿市值 5993.07亿市值 5514.18亿市值 1295.71 213.37 344.69 -0.57(-0.17%) +2.65(+1.26%) +20.46(+1.60%) P&G 宝浩 3693.12亿市值 埃克森美孚 万事达 4956.35亿市值 4749.59亿市值 545.83 110.21 157.52 -3.88(-0.70%) +1.84(+1.70%) -1.45(-0.91%) 彈生 美国银行 s 家得宝 ---- my 3570.70亿市值 3672.75亿市值 3603.73亿市值 152.65 362.21 47.41 +0.36(+0.24%) +0.35(+0.10%) +0.56(+1.19%) t | 联合健康 ASML 阿斯麦 (coglists) 可口可乐 298 ...

7509.86亿市值 8010.18亿市值 7759.36亿市值 288.23 97.23 792.40 +4.17(+1.47%) +0.10(+0.01%) -0.03(-0.03%) 甲骨文 奈飞 VISA 维萨 6367.92亿市值 5951.92亿市值 5474.29亿市值 345.12 211.90 1286.34 -0.14(-0.04%) +1.18(+0.56%) +11.09(+0.87%) PaG 宝浩 3728.29亿市值 埃克森美孚 万事达 4969.11亿市值 4712.81亿市值 547.23 109.36 159.02 -2.47(-0.45%) +0.98(+0.91%) +0.05(+0.03%) 彈生 美国银行 s 家得宝 ---- 3683.46亿市值 3632.30亿市值 3569.20亿市值 153.09 365.08 47.39 +0.81(+0.53%) +3.22(+0.89%) +0.54(+1.15%) t | 联合健康 @gg 可口可乐 ASML 阿斯麦 3007.39亿市值 3098.48亿市值 2769.51亿市值 305.30 787.85 69. ...

金十图示：2025年06月25日（周三）美股热门股票行情一览（美股收盘） 7899.85亿市值 7511.09亿市值 765.74亿市值 97.31 792.53 284.26 +3.00(+1.07%) +14.45(+1.86%) -0.69(-0.70%) 甲骨文 奈飞 VISA 维萨 5920.04亿市值 6382.59亿市值 5427.44亿市值 345.91 1275.33 210.76 -5.72(-1.63%) -4.50(-2.09%) -3.78(-0.30%) PaG 宝浩 3728.53亿市值 埃克森美孚 万事达 4992.17亿市值 4674.67亿市值 549.77 108.47 159.03 -7.76(-1.39%) -1.33(-0.83%) +0.13(+0.12%) 彈生 美国银行 s 家得宝 ---- 10/1 3531.32亿市值 3664.69亿市值 3600.64亿市值 152.31 361.90 46.88 +0.12(+0.08%) +1.48(+0.41%) +0.23(+0.48%) 联合健康 @ggg 可口可乐 ASML 阿斯麦 - 2997.06亿市值 ...

金十图示：2025年06月25日（周三）美股热门股票行情一览（美股盘中） 7539.81亿市值 7874.56亿市值 7771.33亿市值 97.38 795.56 283.35 +2.09(+0.74%) +17.48(+2.25%) -0.62(-0.63%) 甲骨文 奈飞 VISA 维萨 6433.61亿市值 5964.84亿市值 5445.67亿市值 212.36 348.68 1279.62 -2.96(-0.84%) -2.91(-1.35%) +0.51(+0.04%) P&G 宝浩 3740.61亿市值 埃克森美孚 】 万事达 5018.87亿市值 4702.68亿市值 552.71 109.12 159.55 -4.82(-0.86%) -0.81(-0.51%) +0.78(+0.72%) 彈生 美国银行 s 家得宝 -- 10/1 3674.31亿市值 3610.49亿市值 3536.97亿市值 152.71 362.89 46.96 +0.52(+0.34%) +0.30(+0.64%) +2.47(+0.69%) 联合健康 ASML 阿斯麦 @ggfgg 可口可乐 - 3188.17 ...

-0.18(-0.62%) +5.83(+4.08%) +0.92(+0.58%) 淡水河谷 易趣 达美航空 ebav A Delta 384.83亿市值 322.10亿市值 345.59亿市值 74.97 9.02 49.33 -0.20(-2.12%) +0.61(+0.83%) -0.23(-0.46%) 细柯钢铁 诺基亚 爱立信 n i 295.82亿市值 289.54亿市值 280.16亿市值 128.20 5.17 8.31 0.00(0.00%) -0.07(-0.84%) -0.04(-0.67%) 沃达丰(US) Pinterest Inc-A 福克斯-A FOX 244.43亿市值 256.30亿市值 251.67亿市值 55.98 36.12 10.34 -0.10(-0.96%) +0.39(+1.08%) +0.07(+0.13%) 西部数据 (FOX) 福克斯-B (bp) 监管 230.26亿市值 231.06亿市值 218.35亿市值 51.39 24.52 62.59 -0.03(-0.10%) +0.08(+0.16%) +0.52(+0.83%) 华纳音乐 陶氏 哈里伯顿 ...

Core Viewpoint - The innovative pharmaceutical sector is experiencing a resurgence, driven by improved fundamentals, supportive policies, and increased market interest, particularly in the A-share and Hong Kong markets [1][3][12]. Group 1: Market Performance - The pharmaceutical sector has shown strong performance this year, with a notable rebound starting from April 9, despite recent pullbacks [1]. - The innovative drug segment in A-shares and Hong Kong stocks has continued to strengthen, indicating a recovery after four years of adjustment [1][3]. - The total amount of business development (BD) transactions for innovative drugs is projected to rise significantly, from $8.4 billion in 2020 to $51.9 billion in 2024 [4]. Group 2: Policy and Industry Trends - The policy environment has shifted from cost control to encouraging innovation, providing strong support for the development of innovative drugs [3]. - The number and quality of innovative drug products in China have significantly improved, leading to increased interest from foreign pharmaceutical companies [3][5]. - The penetration rate of innovative drugs in China is expected to rise, with current levels at around 20%, compared to 70%-80% in the U.S. [5]. Group 3: Investment Opportunities - Fund managers are optimistic about the future of innovative drugs, emphasizing the importance of technology and growth attributes in the sector [6]. - Investment strategies include focusing on high-quality companies, innovative drug leaders, and traditional pharmaceutical companies transitioning to innovative drugs [7][8][9]. - Investors can consider actively managed pharmaceutical funds or industry-themed ETFs to gain exposure to the innovative drug market [10][12]. Group 4: Fund Performance - Several funds managed by 工银瑞信 have demonstrated strong performance, ranking highly in their respective categories over various time frames [13][15]. - The 工银港股通创新药ETF has seen significant inflows, reflecting market preference for innovative drug companies [11].

Group 1: Drug Approval and Market Expansion - Cloud-based innovative drug company, Yunding Xinyao (1952.HK), has received acceptance for its new drug application (NDA) for Etrasimod (VELSIPITY) for treating moderate to severe active ulcerative colitis (UC) patients from the Korean Ministry of Food and Drug Safety (MFDS), marking a significant step in its Asian market entry [1] - Etrasimod has already been approved in Macau, Singapore, and Hong Kong, with its application in mainland China also accepted, indicating a comprehensive market strategy in Asia [1][5] - The acceptance of the NDA in Korea brings Yunding Xinyao closer to a full market presence in Asia [1] Group 2: Clinical Data and Unmet Needs - Ulcerative colitis is recognized as a modern refractory disease by the World Health Organization, with a significant unmet need in Asia as the number of patients continues to rise [2] - In 2022, approximately 600,000 patients in China were diagnosed with ulcerative colitis, expected to reach 1 million by 2030, while South Korea's patient count is projected to exceed 80,000 by 2030 [2] - Etrasimod is a next-generation selective S1P receptor modulator that shows superior efficacy in achieving deep mucosal healing, which is crucial for reducing disease recurrence and associated risks [2][3] Group 3: Clinical Trials and Efficacy - The NDA application for Etrasimod is based on the results of the ELEVATE UC Phase III registration studies, which included patients who had failed or were intolerant to at least one conventional treatment [3] - The studies demonstrated significant clinical remission and mucosal healing rates, with a 52-week mucosal healing rate of 52% and complete normalization of mucosa at 46% [4] - The clinical value of Etrasimod has been recognized, being included in the 2024 American Gastroenterological Association (AGA) clinical practice guidelines as a first-line treatment for ulcerative colitis [2][3] Group 4: Commercial Potential and Production - Yunding Xinyao has exclusive rights to develop, manufacture, and commercialize Etrasimod in Greater China and South Korea since 2017, with plans for local production to support market needs [5][6] - The company has initiated a production project in Jiaxing, with an investment of 70 million yuan, expected to yield an annual capacity of 50 million tablets, enhancing market potential [6] - Etrasimod is anticipated to reach peak sales of 5 billion yuan, contributing significantly to Yunding Xinyao's product line, alongside other key products [6]

2160.83 四值 2180.27亿中值 2133.48亿中值 135.90 308.43 118.67 +1.90(+1.42%) +8.80(+2.94%) +1.43(+1.22%) Sachs 高盛 9 美国电话电报 M) 麦当劳 AT&T 2035.28亿市值 2031.96亿市值 2084.00亿市值 28.29 662.22 291.45 +15.34(+2.37%) +1.94(+0.67%) +0.09(+0.30%) 加拿大皇家银行 威瑞森通讯 (圖片) 1915.93亿市值 1809.21亿市值 1797.81亿市值 128.26 91.62 42.64 +6.38(+7.48%) +1.07(+0.84%) +0.28(+0.66%) 日事 CAT 卡特彼勒 Q 高通 1797.07亿市值 1754.75亿市值 1709.70亿市值 155.71 373.10 131.07 +1.98(+1.53%) +6.87(+1.88%) +2.57(+1.68%) 11 花旗集团 1515.48亿中值 贝莱德 奥多比 BLACKROCK 同重建 1628.89亿市值 1556.08亿市值 3 ...